Baker BROS. Advisors LP Buys 265,395 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Baker BROS. Advisors LP grew its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,633,838 shares of the company's stock after acquiring an additional 265,395 shares during the period. Stoke Therapeutics comprises about 0.5% of Baker BROS. Advisors LP's portfolio, making the stock its 24th largest holding. Baker BROS. Advisors LP owned 8.75% of Stoke Therapeutics worth $51,111,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in Stoke Therapeutics during the fourth quarter worth about $63,000. Teacher Retirement System of Texas acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $113,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $124,000. Tower Research Capital LLC TRC boosted its stake in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after acquiring an additional 4,918 shares during the period. Finally, Invesco Ltd. acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $133,000.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, Chardan Capital reissued a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of "Buy" and an average target price of $24.67.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by corporate insiders.

Stoke Therapeutics Trading Down 1.0 %

NASDAQ STOK traded down $0.09 during trading on Wednesday, reaching $8.66. The company's stock had a trading volume of 643,398 shares, compared to its average volume of 712,955. The firm has a 50 day moving average price of $7.94 and a 200 day moving average price of $10.13. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $17.58. The firm has a market capitalization of $472.81 million, a price-to-earnings ratio of -4.12 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. On average, equities analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.